New Delhi, February 03, 2021:
- Net revenues in Q3 FY21 at Rs. 113.26 crore, up 15.56 % from Rs. 98.01 crore in Q3 FY20
- Profit before Tax in Q3 FY21 at Rs. 18.16 crore, up 50.71 % from Rs. 12.05 crore in Q3 FY20
- Exports (FOB) in Q3 FY21 at Rs. 61.54 crore, up 4.00 % from Rs. 59.13 crore in Q3 FY20
Financial Highlights (Standalone)
(Amount in Cr except EPS)
| Particulars | Q3 FY21 | Q3 FY20 | Y-O-Y | 9M FY21 | 9M FY20 | Y-O-Y |
| Net Revenue | 113.26 | 98.01 | 15.56% | 339.77 | 307.65 | 10.44% |
| EBITDA | 19.94 | 13.92 | 43.25% | 71.37 | 58.45 | 22.12% |
| Profit before Tax | 18.16 | 12.05 | 50.71% | 66.22 | 52.66 | 25.74% |
| Net Profit | 13.37 | 10.18 | 31.35% | 48.56 | 40.33 | 20.74% |
| E.P.S (Rs.) | 6.68 | 5.09 | 31.35% | 24.28 | 20.17 | 0.40% |
February 02, 2021: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported net profit of Rs. 13.37 crore for the Q3 FY21 ended December 2020 as against net profit of Rs. 10.18 crore in the corresponding period last year, growth of 31.35%. Net revenue for the Q3 FY21 was reported at Rs. 113.26 crore, higher by 15.56% over previous fiscal’s same period net revenue of Rs. 98.01 crore. Company reported EBITDA of Rs. 19.94 crore in Q3FY21, rise of 43.25% as compared to Rs. 13.92 crore in the corresponding period last year. EPS for Q3FY21 was at Rs. 6.68 per share for as compared to Rs. 5.09 in the corresponding period last year.
Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “On back of strong domestic and international business, company posted 15.56 % sales growth, 4.00 % rise in exports and 31.35 % rise in the PAT for the quarter ended Q3FY21. Exports sales in nine months ended December 2020 was reported at Rs. 212.47 crore, growth of 17.56 % Y-o-Y. Geographical and product expansion coupled with operational efficiency contributing to the growth. Company is in the process of expanding presence in Africa, South East Asian countries and exploring entry in EU. Expanding the product basket, company will be introducing 6-7 new products in the domestic markets and expects 20-25 new dossiers approval for the exports market.”
Performance for Nine Months ended December 2020
As a result of expansion in geographical reach in domestic markets, relentless focus on exports and sustained marketing, the Net sales for the nine months ended December 2020 was reported at Rs.339.77 crore, higher by 10.44% over previous fiscal’s same period net sales of Rs. 307.65 crore. Company reported Net profit of Rs. 48.56 crore for the nine months ended December 2020 as against net profit of Rs. 40.33 crore in the corresponding period last year, growth of 20.74 %. EPS for the 9MFY21 was reported at Rs. 24.28 per share. Exports for the 9MFY21 stood at Rs. 212.47 crore, up 17.56 % as against exports of Rs. 180.74 crore in 9MFY20.
To complement company’s strong presence in acute segment, company is also building portfolio in lifestyle and chronic segment especially dermatology, gastro and pain management and plans to introduce them in the EU markets. Company has received EU approval and plans to enter the region soon. Company currently exports to 60 plus countries and plans to expand to 90 plus countries in next 1-2 years.
Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others. Company has filled 25 plus patent applications and is awarded with seven patents. Company has a strong presence in domestic market with good strength of own field force and also exports to more than 60 countries.
Corporate Comm India (CCI Newswire)
